Page 73 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

DPWG guideline for DPYD and fluoropyrimidines
19. Shrestha S, Zhang C, Jerde CR, et al. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther. 2018.
20. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015.
21. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet. 2006;45(6):567-592.
22. Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of 4 patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46(1):9-17.
23. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin
Cancer Res. 2004;10(8):2652-2658.
24. Ciccolini J, Mercier C, Evrard A, et al. A rapid and inexpensive method for anticipating severe toxicity
to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678-685.
25. Zhou ZW, Wang GQ, Wan de S, et al. The dihydrouracil/uracil ratios in plasma and toxicities
of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy.
2007;53(2):127-131.
26. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a
predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-
1424.
27. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation
of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
Pharmacogenomics J. 2013;13(5):389-395.
28. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine
chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity
- Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34.
29. Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat Rev
Drug Discov. 2013;12(1):3-4.
30. Altman RB. Pharmacogenomics: “noninferiority” is sufficient for initial implementation. Clin
Pharmacol Ther. 2011;89(3):348-350.
31. Lunenburg CATC, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the
risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016;54:40-
48.
32. Swen JJ, Nijenhuis M, van Rhenen M, et al. Pharmacogenetic Information in Clinical Guidelines:
The European Perspective. Clin Pharmacol Ther. 2018.
33. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium
guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin
Pharmacol Ther. 2013;94(6):640-645.
34. Loriot MA, Ciccolini J, Thomas F, et al. [Dihydropyrimidine dehydrogenase (DPD) deficiency
screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations
of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105(4):397-407.
35. KNMP. Royal Dutch Society for the Advancement of Pharmacy. Fluorouracil/Capecitabine DPD gene activity score and guidelines. [Website]. 2015; https://kennisbank.knmp.nl/article/
farmacogenetica/2552-4893-4894.html. Accessed 05 May 2017.
71